<DOC>
	<DOC>NCT00624702</DOC>
	<brief_summary>This study will explore information on whether changing the salt formulation of indacaterol affects the incidence of post-inhalation cough.</brief_summary>
	<brief_title>Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Male and female patients 18 to 65 years old (inclusive) Patients with mild to moderate persistent asthma BMI must be within the range of 1832 kg/m2 inclusive Female subjects must: 1. have been sterilized at least 6 months prior to screening 2. be postmenopausal with no regular bleeding for at least a year prior to inclusion Patients with lifethreatening arrhythmias Patients with COPD or diabetes mellitus History of immunocompromise, including a positive HIV A positive Hepatitis B surface antigen (HBsAg) of Hepatitis C test result Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Asthma, cough, spirometry, maleate, xinafoate, acetate, SDDPI (single dose dry powder inhaler)</keyword>
</DOC>